Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …

Many patients with systemic autoimmune rheumatic diseases (SARDs) require
immunosuppression to reduce disease activity, but this also has important possible …

Objective To examine the frequency of, and risk factors for, disease flare following COVID-19
vaccination in patients with systemic rheumatic disease (SRD). Methods An international …

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28
days or longer, among people with systemic autoimmune rheumatic diseases (SARDs) …

Background There is a paucity of data on outcomes for people with gout and COVID-19. We
aimed to assess whether gout is a risk factor for diagnosis of COVID-19 and COVID-19 …

Objective The goal of this study was to ascertain COVID‐19 vaccine uptake, reasons for
hesitancy, and self‐reported flare in a large rheumatology practice‐based network. Methods …

Objectives To explore barriers and facilitators to COVID-19, influenza, and pneumococcal
vaccine uptake in immunosuppressed adults with immune-mediated inflammatory diseases …

Introduction: Vaccines are the best tools to end the pandemic, and their public acceptance is
crucial in achieving herd immunity. Despite global efforts to increase access to vaccination …

Background Although patients with rheumatic and musculoskeletal diseases (RMDs) are at
increased risk for adverse outcomes of COVID-19 illness compared to healthy controls, they …

Objective COVID-19 vaccines have a favorable safety profile in patients with autoimmune
rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however …